Breast-Conserving Therapy in Early Breast Cancer

Dongmo R, MD ¹, Vlastos G, MD ²

¹ University of Yaoundé I, Department of Obstetrics/ Gynecology, Yaoundé, Cameroon

² Geneva University, Department of Obstetrics/ Gynecology, Geneva, Switzerland

Breast Cancer

Incidence: 1 050 346 new cases / year ¹

• Mortality: 372 969 deaths / year


• Frequency: 1/8 woman²

1. WHO, Geneva, Globocan, 2000.

2. Green Lee et al. Ca Cancer J Clin, 2000.

Cancer Statistics, 2000

10 Leading Sites by Gender, US



30 % Breast

12 % Lung, bronchus

11 % Colon, rectum

6 % Uterine corpus

4 % Ovary

4 % NH-lymphoma

3 % Melanoma

2 % Urinary bladder

2 % Pancreas

2 % Thyroid

22 % All other sites

29 % Prostate

14 % Lung, bronchus

10 % Colon, rectum

6 % Urinary bladder

5 % NH-lymphoma

4 % Melanoma

3 % Head, neck

3 % Kidney

3 % Leukemia


2 % Pancreas

19 % All other sites



Breast Cancer: Incidence

Incidence rate (per 100,000 women)



Surgical Options for Early Breast Cancer

• 1907: Radical mastectomy (Halsted)

• 1960: Modified radical mastectomy (Patey)

• 1970: Breast- Conserving Therapy (BCT)

Objective

To review breast-conserving therapy as a treatment option for early breast cancer

Methodology

MEDLINE

Cochrane Library WHO
Reproductive
Health Library

Randomized Trials


BCT: Definition

Breast- conserving surgery

+

Radiation therapy

Surgical Technique



Lymph Node Status

Axillary lymph nodes dissection

Sentinel node biopsy

Sentinel Node

Study	Year	#Pts	ID rate	Tech-	Accu-	SLN
				nique	racy	only met
Giuliano	1 994	174	66%	Dye	96%	38%
Krag	1 996	70	71%	Тс	100%	67%
Albertini	1 996	62	92%	Tc + Dye	100%	67%
Giuliano	1 997	107	93%	Dye	100%	67%
Borgs tein	1 997	25	100%	Tc*+ Dye	100%	64%
Barn well	1 998	42	90%	Tc + Dye	100%	33%
Vero nesi	1 997	163	98%	Dye*	98%	40%
Borgs tein	1 998	104	100%*	Tc	98%	59%
Crossin	1 998	50	84%	Tc	98%	
Guenther	1 997	145	71%	Dye	97%	43%
Krag	1 998	443	91%	Tc	96%	41%

Indication of BCT

• Stage I 1: T1 N0 M0 2

• Stage II: T0 N1 M0 T1 N0 M0 T2 N0 M0 T2 N1 M0

^{1.} American Joint Commitee on Cancer (AJCC), 1997.

^{2.} Union International Contre le Caner (UIAC), 1994.

Limitations of BCT

Absolute

- Multicentric
- Diffuse calcifications
- Positive margins
- Prior irradiation

Relative

- Tumor / breast ratio
- Collagen diseases
- Advanced disease
- Central tumor

BCT: Outcome

Local recurrence

Survival

Cosmetic

Prognostic factors

BCT: Local Recurrence

			Number of patients		Local recurrence	
Trial	Period	Follow-up (Years)	Mast	CS/RT	Mast (%)	CS/RT (%)
NCI- Milan	1973-80	18	349	352	4	7
IGR	1972-84	15	91	88	14	9
NSABP B-06	1976-84	12	590	629	8	10
NCI - Bethesda	1979-87	10	116	121	6	19
EORTC	1980-86	8	422	452	14	17
DBCG	1983-89	6	429	430	4	3

[•] CS/RT, Conservative Surgery and X-ray therapy; DBCG, Danish Breast Cancer Group; eortc, European organization for Research and Treatment of Cancer; IGR, Institut Gustave-Roussy; Mast, Mastectomy; NCI, National Cancer Institute; NSABP, National Surgical Adjuvant Breast and Bowel Project.

BCT: Overall Survival

			Number of patients		Overall Survival	
Trial	Period	Follow-up (Years)	Mast	CS/RT	Mast (%)	CS/RT (%)
NCI- Milan	1973-80	18	349	352	73	65
IGR	1972-84	15	91	88	65	65
NSABP B-06	1976-84	12	590	629	63	59
NCI- Bethesda	1979-87	10	116	121	77	75
EORTC	1980-86	8	422	452	54	61
DBCG	1983-89	6	429	430	82	79

CS/RT, Conservative Surgery and X-ray therapy; DBCG, Danish Breast Cancer Group; eortc, European organization for Research and Treatment of Cancer; IGR, Institut Gustave-Roussy; Mast, Mastectomy; NCI, National Cancer Institute; NSABP, National Surgical Adjuvant Breast and Bowel Project.

Cosmetic: Prognostic Factors

Type of surgery

Radiation therapy

BCT: Prognostic Factors

- Age
- Tumor size
- Histology
- Margins
- Lymph nodes
- Radiation therapy
- Systemic treatment

Prognostic Factors: Age

Tumor characteristics

Loco- regional recurrence

• Survival

Prognostic Factors: Tumor Size

			Local recurrence rate		
Trial	Follow-Up (Years)	Tumor Size (cm)	Mast (%)	CS/RT (%)	
NCI - Milan	18	2	4	7	
IGR	15	2	14	9	
NSABP B-06	12	4	8	10	
NCI - Bethesda	10	5	6	19	
EORTC	8	5	14	17	
DBCG	6	5	4	3	

CS/RT, Conservative Surgery and X-ray therapy; DBCG, Danish Breast Cancer Group; eortc, European organization for Research and Treatment of Cancer; IGR, Institut Gustave-Roussy; Mast, Mastectomy; NCI, National Cancer Institute; NSABP, National Surgical Adjuvant Breast and Bowel Project.

Prognostic Factors: Histology

• Extensive Intraductal Component (EIC)

Lobular carcinoma

Grade

Margins


Prognostic Factors: Type of Surgery

Local recurrence

Mastectomy < Quadrantectomy < Lumpectomy

$$3 - 4\%$$

Prognostic Factors: Lymph Nodes



Prognostic Factors: Radiation Therapy

		Local recurrence		Survival	
Trial	Median follow-up (Months)	CS (%)	CS + RT (%)	CS (%)	CS + RT (%)
NSABP B-06	144	38	12	58	62
NCI-Milan III	52	18	2		_
Swedish	64	18	2	90	91
Antorio	91	35	11	76	79

CS, Conservative Surgery; CS/RT, Conservative Surgery and Radiation therapy; NCI, National Cancer Institute; NSABP, National Surgical Adjuvant Breast and Bowel Project.

Prognostic Factors: Sytemic Treatment

Chemotherapy



Hormonal Treatment

Conclusion

• Breast- Conserving Therapy is a safe procedure

Conclusion

Breast- Conserving Therapy provides

- Good Locoregional Control
- Distant Survival = Mastectomy
- Good Cosmetic Results
- Better Quality of Life

Recommendations

• Screening

Follow-up